Physician profile
James S Lee
NPI 1902909377
$2,342.14
in general payments reported to CMS, 2019-2025
14 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $341 · 2021: $436 · 2022: $11.79 · 2023: $153 · 2024: $264 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $639.78 | 2019-2024 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $360.43 | 2019-2020 | |
| Amgen INC. | $253.80 | 2022-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $247.49 | 2019 | |
| Glaxosmithkline, LLC. | $239.94 | 2023-2024 | Arexvy |
| Pfizer INC. | $142.20 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $123.62 | 2019 | |
| Aytu Biopharma, INC. | $98.15 | 2019-2020 | |
| Lilly USA, LLC | $35.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2021 | |
| Mannkind Corporation | $17.84 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.